Surface Oncology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SURF research report →
About the company
Surface Oncology, Inc. is a clinical-stage biotechnology firm focused on discovering and developing innovative immuno-oncology treatments for cancer patients in the United States. Its pipeline features a range of antibody-based therapeutics, including NZV930, a fully human IgG4 monoclonal antibody designed to modulate extracellular adenosine production, and SRF617, another human IgG4 monoclonal antibody that aims to block CD39's enzymatic activity, thereby influencing adenosine levels and ATP degradation.
- CEO
- Lisa McGrath
- IPO
- 2018
- Employees
- 35
- HQ
- Cambridge, MA, US
Price Chart
- Market Cap
- $65.08M
- P/E
- -0.91
- P/S
- 2.17
- P/B
- 0.64
- EV/EBITDA
- -1.13
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -206.23%
- Net Margin
- -217.68%
- ROE
- -61.52%
- ROIC
- -41.40%
- Revenue
- $30.00M · 1016.49%
- Net Income
- $-65,303,000 · 17.82%
- EPS
- $-1.17 · 35.00%
- Op Income
- $-61,869,000
- FCF YoY
- 3.87%
- 52W High
- $1.43
- 52W Low
- $0.56
- 50D MA
- $0.96
- 200D MA
- $0.82
- Beta
- 1.75
- Avg Volume
- 798.15K
Get TickerSpark's AI analysis on SURF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 8, 23 | Sigal Charles Elliott | sell | 113,636 |
| Sep 8, 23 | Sigal Charles Elliott | sell | 45,453 |
| Sep 8, 23 | Adams Chandra | sell | 50,000 |
| Sep 8, 23 | Adams Chandra | sell | 23,884 |
| Sep 8, 23 | RATH HENRY C. | sell | 44,971 |
| Sep 8, 23 | RATH HENRY C. | sell | 150,000 |
| Sep 8, 23 | Palombella Vito J. | sell | 87,212 |
| Sep 8, 23 | Palombella Vito J. | sell | 150,000 |
| Sep 8, 23 | Goater Jeff | sell | 129,222 |
| Sep 8, 23 | FEES JESSICA | sell | 101,915 |
Our SURF coverage
Recent articles, reports, and earnings notes.
No research on SURF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SURF report →Similar companies
Peers in the same neighborhood.